MAPT and Alzheimer disease: It has been established that CSF p-tau levels increase while CSF Aβ levels decrease in AD [74,75,76]; the plasma ratio Aβ42/Aβ40 and p-tau181 protein can distinguish between AD and a healthy state [77,78,79,80].